Biomarker is a biological
molecule, measured in biological samples for instance blood, urine and saliva.
It is used to effectively & accurately evaluate pharmacologic responses,
biological procedures and pathogenic procedures. It is also known as signature
molecule or molecular marker. Various biomarkers are available for biological
systems such as cardiovascular system, immune system and metabolic system. It
is also used to detect, predict disease vulnerability and monitor disease
progression for infectious diseases, metabolic diseases, cancer, central
nervous system disease and autoimmune diseases.
According
to study, “Global
Biomarker Market Size study, by Disease Indication (Cancer, Cardiovascular
Disorder, Infectious Diseases, Neurological Disorder, Immunological Disorder,
Others), by Application (Diagnosis, Drug Discovery and Development, Others), by
End-Use (Hospitals, Research Laboratories, Ambulatory Surgical Centers,
Diagnostic Laboratories), by Product Type (Biomarker Test Kits, Biomarker
Analyzers) and Regional Forecasts 2018-2025” the key companies
operating in the global biomarker market are Abbott Laboratories Inc., BG
Medicine Inc., Medtronic, Siemens Healthcare GmbH, F. Hoffmann LA Roche Ltd.,
Qiagen N.V., Nexus-DX, Lifesign LLC, 23andMe, Aushon BioSystem Inc., Merck
& Co. Inc., Thermo Fisher Scientific Inc., Roche Diagnostics Ltd.,
PerkinElmer Inc., Enzo BIochem Inc., Eisai Co. Ltd., Bio-Rad Laboratories Inc.,
EKF Diagnostics Holdings, Inc., Biosims Technologies Sas, G.E. Healthcare Inc.,
Meso Scale Diagnostics, LLC., Agilent Technologies Inc., Signosis, Inc., Epistem
Ltd., Cisbio Bioassays, Ambry Genetics, Quest Diagnostics, Biomerieux,
Illumina, Inc., Hologic, Inc. The key vendors are developing novel kits &
therapies or drugs to target population in the areas with high unmet clinical
needs.
Based
on type, biomarker market is
segmented into safety biomarkers, validation biomarkers and efficacy
biomarkers. Efficacy biomarkers are further sub-segmented into surrogate
biomarkers, predictive biomarkers, prognostic biomarkers and pharmacodynamic
biomarkers. Based on disease indication, market is segmented into cancer,
cardiovascular disorders, neurological disorders, immunological disorders and
others (renal disorders, diabetes, urinal diseases, and tuberculosis). Based on
services, market is segmented into tests, drug discovery, therapies, drug
formulation and others. Based on profiling technologies, market is segmented
into OMICS technology, immunoassays, imaging technology, bioinformatics and
cytogenetics. OMICS technology is further sub-segmented proteomics,
transcriptomics, genomics, and metabolomics. Imaging technology is further
sub-segmented into Positron Emission Tomography (PET), ultrasound,
Single-Photon Emission Computed Tomography (SPECT), Computed Tomography (CT)
and magnetic resonance imaging (MRI). Additionally, bioinformatics segment is
further sub-segmented into data mining, cluster analysis,
cell signal pathways, statistical analysis, computer aided design, and protein
interaction maps. In addition, based on
application, market is segmented into disease diagnosis, risk assessment,
development of molecular diagnostic, drug discovery & development, forensic
application, drug formulation, DNA fingerprinting and others.
The biomarker market is driven by increase
in diagnostic applications of biomarkers (companion diagnostics and
personalized medicine), followed by high prevalence of cancer, rise in R&D
funding for pharma & biotech companies, higher adoption rate of biomarkers
technologies, increase in number of CROs & low cost of clinical trials in
developing countries and new initiatives for biomarker research. However, poorly
suited regulatory & reimbursement systems, high capital investments &
low cost-benefit ratio and technical issues related to sample collection and
storage may impact the market. Moreover, increase in demand of personalized
medicine and growth in importance of companion diagnostics are key
opportunities for market.
Based on geography, the
North-American region dominates the biomarker market of biomarkers owing to
rise in demand of aging population for diagnosis and treatment of age related
diseases in the region. The Asian-pacific region is expected to witness high
growth rates due to increase in research and development (R&D) activities
and rise in number of contract research organizations over the forecast period.
For more
information, refer to below link:-
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
